Biography
Kelly Han is a member of the Firm's Transactional Group. Her practice focuses on cross-border M&A and joint venture transactions. She also has extensive experience assisting companies with the planning and implementation of complex, multijurisdictional corporate reorganization and restructuring projects, including post-acquisition integrations, business separations and spin-offs, and entity rationalizations. In addition, she advises clients in relation to general corporate and regulatory matters and commercial agreements.
Representative Legal Matters
- Advised a US-headquartered leading global chemical company in its advanced chemical product greenfield project in Shanghai with a total investment of up to approximately RMB 11.6 billion.
- Advised Mondelez on its acquisition of a majority stake in China Evirth group, an advanced frozen pastry producer in China, from more than 20 sellers.
- Advised Hengten Networks on its acquisition of the entire issued share capital in Virtual Cinema Entertainment for a consideration of HKD 7.2 billion.
- Advised CBC Group funded Hasten Biopharmaceutical in the acquisition of the asset rights of 14 branded products valued at approx. USD 150 million across Pan-Asia countries and regions (including South Korea, Singapore, Thailand, Australia, China Hong Kong SAR) from Celltrion, a Korean biopharmaceutical company.
- Advised a diversified international management and holding company and its affiliate on three parallel acquisition of state-owned equity interest in a major Chinese asset management company through public listing at two Chinese exchanges for considerations of over RMB 4.2 billion.
- Advised one of the largest US privately held conglomerates on its spin-off of apparel and advanced textile business in Asia Pacific, covering operations in nine jurisdictions (including mainland China, Hong Kong, Singapore, Japan, Korea, Taiwan, Australia, Thailand, India) and more than 20 entities.
- Advised a leading European fashion company in disposal of its equity interests in a winery in the PRC.
- Advised a UK-headquartered leading pharmaceutical company in the buy-out of a minority shareholder in its China vaccine manufacturing joint venture and subsequent sale of the China subsidiary to offshore and domestic purchasers.
- Advised a US-headquartered leading food company in its buy-out of the Chinese partner in a Sino-foreign joint venture company in Shanghai through public listing at the Shanghai United Asset and Equity Exchange.
- Leading 70+ restructuring projects for one of the largest US privately held conglomerate across Asia jurisdictions.
Admission
PRC (2021)
New York, USA (2017)
Education
Columbia University (LL.M., James Kent Scholar honor) (2016)
Fudan University (LL.B.) (2012)
Languages
English
Mandarin
Japanese